NCT00450190View on ClinicalTrials.gov

Saizen® E-Device User Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

September 30, 2006

Study Completion Date

September 30, 2006

Conditions
Growth Disorders
Interventions
DEVICE

Saizen® E-Device

Saizen® (recombinant human growth hormone \[r-hGH\]) injection 8 milligram (mg) per 137 milliliter (mL) will be administered using an electronic auto-injector (E-Device) subcutaneously (SC) in the evening as per local Summary of Product Characteristics (SmPC) for 60 days.

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT00450190 - Saizen® E-Device User Trial | Biotech Hunter | Biotech Hunter